Uğur Şahin gives a date for the cancer vaccine
Prof. Dr. Uğur Şahin, co-founder and CEO of the German biotechnology firm BioNTech, announced that they expect the first mRNA-based cancer vaccines to be approved before 2030.
Speaking to the German newspaper Bild am Sonntag, Uğur Şahin stated, "We expect our first mRNA-based cancer vaccines to be approved before 2030. We also plan to have trial data for other therapeutic approaches between 2025 and 2029."
Emphasizing that their goal is to develop personalized cancer vaccines for every patient, Şahin said, "To do this, we analyze the cancer characteristics of each patient and select those that will enable the immune system to recognize and destroy as many tumor cells as possible."
Pointing to antibody-drug conjugates (ADCs) as another source of hope, Şahin added, "ADCs are antibodies that carry chemotherapy. They circulate in the blood, reach the tumor, and release the chemotherapy there in a targeted manner. The importance of this treatment is that it can shrink the tumor very quickly in a significant portion of participants. I am confident that within a few years, more and more ADCs will be used as targeted chemotherapy instead of classic chemotherapy in many cancer cases."
News Source: AA
Most Read
Galatasaray announces injury updates for Osimhen, Lemina, and Singo
Attention online sellers: Tax monitoring expanded
VAR for the Fenerbahçe-Beşiktaş derby has been announced!
Bridges and highways are being privatized: 15 July and FSM are also on the list
Peugeot September 2026 price list is out
New details emerge in 'panel' operation targeting lawyers
Gökçek era detail in ABB investigation
Özlem Şanver: 'He said he would change, I believed him; should I be beaten just because I didn't leave?'
First statement from Osimhen after injury in Başakşehir match
The Süper Lig's new team becomes the transfer champion